How Much Did Poly Group Raise?
Funding & Key Investors

Poly Group has solidified its market position through a significant capital infusion, reaching a total funding milestone of $634K. This recent strategic investment of $634K underscores the firm's commitment to scaling its proprietary antimicrobial technology. By securing this financing, the company is well-positioned to accelerate its commercialization efforts across diverse industrial sectors, moving beyond initial development phases into a period of rapid market penetration and operational expansion.

What is Poly Group?

Poly Group
Business ServicesResearch & Development

Poly Group serves as the exclusive licensor of Nouvex, a sophisticated antimicrobial additive engineered to mitigate the presence of bacteria, viruses, and fungi. Originating from research conducted at Purdue University, the Nouvex technology represents a paradigm shift in surface protection, offering a non-toxic alternative to traditional chemical agents that often struggle with bacterial resistance. The company operates at the intersection of material science and public health, providing essential solutions for textiles, building materials, healthcare infrastructure, and consumer goods. By integrating its additive into manufacturing processes, Poly Group enables partners to enhance product longevity and hygiene standards, effectively addressing the growing global demand for proactive sanitation solutions in high-traffic environments.

How much funding has Poly Group raised?

Poly Group has raised a total of $634K across 1 funding round:

2015

Private Equity

$634K

Private Equity (2015): $634K, investors not publicly disclosed

Key Investors in Poly Group

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for Poly Group?

With the recent capital injection, Poly Group is poised to transition into a phase of aggressive market adoption. The strategic roadmap likely involves scaling production capabilities to meet the requirements of large-scale commercial and industrial partners. Furthermore, the company is expected to leverage its intellectual property to forge new licensing agreements, thereby diversifying its revenue streams across global markets. As the regulatory landscape for antimicrobial materials continues to evolve, Poly Group's focus on non-toxic, high-efficacy solutions provides a competitive moat. Future growth will be driven by the integration of Nouvex into high-volume consumer product lines and the expansion of its technical support infrastructure to facilitate seamless adoption by global manufacturing entities. Keywords: antimicrobial technology, Nouvex, material science, surface protection, industrial hygiene, venture financing, strategic growth, public health innovation.

See full Poly Group company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Business Services industry

Business ServicesSoftware TestingProject Management
Business ServicesCommercial Printing
Advertising NetworksBusiness Services
Business ServicesHuman Resources Management Systems (HRMS)

Frequently Asked Questions Regarding Poly Group Financial Insights

What are the most recent funding rounds that Poly Group has completed, and what were the funding rounds?
Poly Group has recently completed 1 funding rounds: Private Equity on Oct 1, 2015.
What is the total amount of funding Poly Group has raised to date?
Poly Group has raised a total of $634K in funding to date.
How many funding rounds has Poly Group completed?
Poly Group has completed 1 funding rounds.
How much funding did Poly Group raise in its most recent funding round?
Poly Group raised $634K in its most recent funding round.
Which was the largest funding round in Poly Group's history?
The largest funding round in Poly Group's history was $634K.
See more information about Poly Group